CJC-1295 is one of the more talked-about peptides in longevity and fitness circles, but it’s also sitting in one of the messiest regulatory situations of any compound in this space right now. Depending on which source you read, it’s either on its way back to being legally compoundable or still effectively restricted — and as of mid-2026, credible sources genuinely disagree on which is currently true. That’s not a reason to ignore the topic, but it is a reason to be skeptical of any article, including this one, that states its legal status with total confidence.
This guide covers what CJC-1295 actually is, how it works, why its FDA compounding status has been in flux, what the safety data shows, and how to think about sourcing if you’re considering it, without pretending the regulatory picture is more settled than it actually is.
What Is CJC-1295?
CJC-1295 is a synthetic peptide built from the first 29 amino acids of growth hormone-releasing hormone (GHRH) — the portion of the molecule responsible for its biological activity — modified to resist the rapid breakdown that limits natural GHRH to a half-life of just a few minutes. By stabilizing that structure, CJC-1295 prompts the pituitary gland to release growth hormone in a pulsatile pattern that mimics the body’s natural rhythm, rather than flooding the bloodstream with a constant, artificial level the way direct HGH injection does.
It comes in two distinct forms that get discussed somewhat interchangeably, which causes real confusion: CJC-1295 with DAC (Drug Affinity Complex) is modified further to extend its activity for roughly a week per dose, while CJC-1295 without DAC — often called Mod GRF 1-29 — has a much shorter half-life and requires more frequent dosing. These are meaningfully different products in terms of dosing frequency and how they’re typically used, despite sharing a name.
Why CJC-1295 Was Never FDA-Approved
Unlike sermorelin, which was briefly an approved drug before being discontinued, CJC-1295 has never received FDA approval for any indication. It was originally developed by a company called ConjuChem and advanced into Phase 2 clinical trials for HIV-associated lipodystrophy, following a similar rationale to tesamorelin, a related GHRH analog that did eventually receive FDA approval for that specific condition in 2010. ConjuChem’s development of CJC-1295 was discontinued for commercial and financial reasons rather than because of a specific safety failure in the trials, though the drug never completed the pivotal trials required for approval.
That incomplete trial history matters for how regulators currently view it: there’s meaningfully less human safety and efficacy data on CJC-1295 than exists for approved GHRH analogs, which is a central reason it’s been treated more cautiously in recent compounding regulation.
The Current Regulatory Picture Is Genuinely Unsettled
Here’s where it’s important to be direct about the limits of any online guide’s certainty, including this one.
In late 2023, the FDA placed CJC-1295, along with roughly 18 other peptides including BPC-157 and ipamorelin, on its Section 503A “Category 2” bulk drug substance list — a designation that generally prevents traditional compounding pharmacies from preparing a substance for routine patient use, citing concerns including limited safety data and unresolved questions about the compound’s dual DAC and non-DAC forms.
Since then, the situation has shifted multiple times. In September 2024, CJC-1295 was among several peptides referred for formal review by the FDA’s Pharmacy Compounding Advisory Committee after the original nomination was withdrawn — a necessary step toward potential reclassification, but not itself a restoration of compounding access. In early 2026, public statements from federal health officials signaled an intent to move CJC-1295 and several related peptides back toward compounding eligibility. By April 2026, some reporting indicated CJC-1295 had been removed from the Category 2 list without yet being formally added to Category 1, leaving it in a regulatory gap pending further committee review — while other sources reported around the same time that CJC-1295 was specifically not among the peptides that were reclassified in that April update, and remained more restricted than compounds like ipamorelin.
Given that conflict between sources, the honest answer is that CJC-1295’s compounding status is actively in motion and not something to take as settled from any single article, including this one. If you’re considering this compound, checking the FDA’s current bulk drug substances list directly, or asking a prospective prescriber and compounding pharmacy for their current understanding of where CJC-1295 stands, will give you a more accurate answer than any general guide can promise given how recently this has been changing.
What the Safety Data Actually Shows
CJC-1295’s safety profile draws from a mix of its limited formal trial data and post-market reports gathered as it circulated through compounding and gray-market channels.
Commonly reported side effects include injection site reactions, flushing, headache, and water retention related to elevated growth hormone levels. Because CJC-1295 works by raising GH and IGF-1, monitoring these markers is the standard way to track whether it’s producing the intended effect, and elevated levels over time carry the same general risks associated with excess growth hormone signaling — including increased blood sugar and, with sustained elevation, concerns about long-term IGF-1 exposure.
More specific to CJC-1295, regulatory reviews have also cited reports of heart-related side effects as part of the broader safety concerns behind its Category 2 designation, on top of general concerns about impurities and immune response that apply across compounded peptides more broadly. This is a meaningful part of why the compound has drawn more regulatory caution than some others in its class.
It’s also worth knowing that CJC-1295 is a banned substance under World Anti-Doping Agency rules, which matters directly for anyone competing in a tested sport.
Compounded Prescription vs. Research Chemical: The Distinction That Matters Most
Regardless of exactly where CJC-1295’s Category 2 status lands at any given moment, the distinction between how it’s obtained remains the single biggest safety factor.
A legitimate compounded prescription involves a licensed physician evaluating your health history, a licensed compounding pharmacy preparing the product under regulatory oversight (503A pharmacies under state board oversight, or 503B facilities under FDA-registered manufacturing standards), and typically some form of lab monitoring, particularly IGF-1 levels, built into ongoing care.
“Research chemical” CJC-1295, sold online labeled “not for human consumption,” involves none of that. There’s no clinician evaluating whether it’s appropriate for your health profile, no pharmacy oversight, and no verification that what’s in the vial matches the label. Independent testing of gray-market peptides sold this way has repeatedly turned up underdosed, contaminated, or misidentified products — a risk that’s especially relevant for a compound like CJC-1295, where the DAC and non-DAC forms are sometimes sold under the same name despite being meaningfully different products with different dosing needs.
If CJC-1295’s compounding status opens up further in your area, working through a licensed prescriber and a reputable compounding pharmacy remains a substantially safer path than a research-chemical purchase, even at a higher price point.
Questions Worth Asking Before Considering CJC-1295
If a clinic or provider is offering CJC-1295, a few questions can help you gauge how seriously they’re treating both the regulatory and safety picture:
- Can they confirm their current understanding of CJC-1295’s compounding status, and where they’re sourcing it from?
- Is it the DAC or non-DAC form, and do they explain why one is being recommended over the other for your goals?
- Will baseline and follow-up IGF-1 monitoring be part of your protocol?
- Are they aware of and willing to discuss the reported cardiac safety signals behind its regulatory scrutiny?
- What’s their plan if the regulatory status changes again during your treatment?
A provider who can’t answer these directly, or one who waves off the regulatory uncertainty entirely, is worth reconsidering.
Frequently Asked Questions
Is CJC-1295 legal in the United States? Its legal status depends on its current FDA bulk drug substance category, which has changed multiple times since 2023 and remains unsettled as of mid-2026. It’s never been an FDA-approved drug, and whether a compounding pharmacy can legally prepare it depends on its category status at any given moment — this is worth confirming directly with the FDA’s current list or a licensed provider rather than relying on any single source.
What’s the difference between CJC-1295 with DAC and without DAC? The DAC version is modified for extended activity, typically dosed about once or twice a week. The non-DAC version, also called Mod GRF 1-29, has a much shorter half-life and requires more frequent dosing. They’re often discussed under the same name despite being functionally different products.
Is CJC-1295 the same as sermorelin? No, though both are GHRH analogs that work through a similar mechanism. Sermorelin has a prior FDA approval history for a diagnostic indication, which gives it a somewhat stronger regulatory foundation, while CJC-1295 never completed the clinical trial process for any approved use.
Is it safe to buy CJC-1295 as a research chemical online? No reputable medical source recommends this. Products sold this way lack clinician oversight, pharmacy quality control, and verified contents, and independent testing has found real issues with underdosing, contamination, and misidentification in peptides sold through unregulated channels.
Why does CJC-1295 face more regulatory scrutiny than some other peptides? Regulatory reviews have cited limited completed safety trial data, questions related to its two distinct forms being sold under one name, and specifically reported cardiac-related safety signals, in addition to the general impurity and immune-response concerns that apply across compounded peptides.
Key Takeaways
CJC-1295 is a scientifically legitimate mechanism — GHRH stimulation of natural growth hormone release — attached to a genuinely unresolved regulatory situation and a safety profile that includes specific concerns beyond the general risks shared across this peptide category. If you’re considering it, the two things worth prioritizing over any specific protocol are confirming its actual current legal status through a direct, current source, and, if you proceed, working exclusively through a licensed prescriber and legitimate compounding pharmacy rather than an unregulated online seller.
For related reading, you may also want to check out our guides on sermorelin’s regulatory history and how IGF-1 monitoring works for anyone considering GH-axis peptide therapy. Given how quickly this regulatory picture has been moving, a conversation with a licensed physician who can confirm current rules is a more reliable next step than any static article, including this one.